Status:
COMPLETED
Diagnostic Accuracy of MRI, DWI MRI, FDG-PET/CT and FEC PET/CT in the Detection of Lymph Node Metastases in Surgically Staged Endometrial and Cervical Carcinoma
Lead Sponsor:
Barts & The London NHS Trust
Collaborating Sponsors:
Birmingham Women's NHS Foundation Trust
Case Western Reserve University
Conditions:
Surgically Staged Endometrial and Cervical Carcinoma
Cervical Cancer: Invasive Disease, FIGO Stage 1B1 or Higher
Eligibility:
FEMALE
18+ years
Brief Summary
This is a prospective diagnostic performance study which compares three new imaging methods with the current standard imaging method for the diagnosis of metastatic lymph nodes.
Detailed Description
The aim is to demonstrate whether leading edge molecular imaging technologies (FDG-PET/CT, DW-MRI and Fluoro-ethyl-choline (FEC) PET/CT) can identify lymph node metastases with sufficient accuracy to ...
Eligibility Criteria
Inclusion
- Females 18 years or older; (no upper limit).
- Patients with histologically confirmed cancer of the cervix or endometrium.
- In patient with cervix cancer, there must be confirmation of invasive disease; FIGO stage 1B1 or higher FIGO stage demonstrated clinically and/or on MRI. In patients with advanced disease being considered for chemoradiotherapy treatment, patients may be considered for entry if nodal lymphadenectomy is being used to inform radiotherapy planning;
- In patients with endometrial cancer, a) stage 1A with myometrial invasion or any higher stage and grade 3 b) stage 1A with myometrial invasion or any other higher stage and serous papillary or clear cell sub-types
- stage II disease or above and any histology grade The MDT decision may be based on the combination of tumour characteristics on histology, clinical and imaging findings.
- No contra-indication to FDG-PET/CT, FEC-PET/CT or MRI.
- Fit for surgical lymphadenectomy, as determined by the local MDT. The patient should also be considered fit for extended field radiotherapy in cases where lymphadenectomy is being undertaken to inform radiotherapy planning.
- The extent of lymph node dissection will be made by the local multidisciplinary team, based on the presence of risk factors for lymph node metastases, according to the protocol. Patients must be considered fit to undergo lymph node dissection.
- Able and willing to give written informed consent and to comply with the study protocol procedures
Exclusion
- Known contra-indication to MRI or PET/CT scan.
- Known allergy to FDG or FEC.
- Not considered fit for lymphadenectomy (open or laparoscopic) or, where appropriate, radiotherapy, as determined by the local MDT.
- If the patient is pregnant or breast-feeding.
- Females of childbearing potential must be willing to use an effective method of contraception (hormonal or barrier method of birth control) from the time consent is signed until 6 weeks after the last PET/CT scan unless undergoing hysterectomy.
- Note: subjects are not considered of childbearing potential if they are surgically sterile (they have undergone bilateral tubal ligation or bilateral oophorectomy) or they are postmenopausal
- Females of childbearing potential must have a negative pregnancy test within three weeks prior to being registered for the study.
- Participation in another Clinical Trial of an Investigational Medicinal Product (CTIMP). If patient's have recently completed a CTIMP trial they must have had their last dose(s) of study drug prior to their first imaging procedure on the MAPPING study.
- Participation in another clinical trial (CTIMP or non-CTIMP) where the protocol contains imaging procedures that would occur during the MAPPING study.
- Medical or psychiatric illness, which makes the patient unsuitable or unable to give informed consent.
Key Trial Info
Start Date :
June 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2018
Estimated Enrollment :
162 Patients enrolled
Trial Details
Trial ID
NCT01836484
Start Date
June 1 2012
End Date
December 1 2018
Last Update
February 13 2020
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Elizabeth Hospital, Birmingham University Hospitals, Birmingham NHS Foundation Trust
Birmingham, United Kingdom, B15 2TH
2
Birmingham City Hospital, Sandwell & West Birmingham Hospitals NHS Trust
Birmingham, United Kingdom, B18 7QH
3
St Bartholomew's Hospital, Barts Health NHS Trust
London, United Kingdom, EC1A 7BE
4
University College London Hospital
London, United Kingdom, NW1 2BU